Developed by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inflammatory drugs. It is currently under evaluation as a treatment for osteoarthritis (OA), the most common form of arthritis. Although phase III trials have been successfully completed in OA patients no dates for regulatory submission have yet been given.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aliskiren | The risk or severity of renal failure and hypertension can be increased when Licofelone is combined with Aliskiren. |
| Deferasirox | The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Licofelone is combined with Deferasirox. |
| Desmopressin | The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Licofelone is combined with Desmopressin. |
| Digoxin | Licofelone may decrease the excretion rate of Digoxin which could result in a higher serum level. |
| Metildigoxin | Licofelone may decrease the excretion rate of Metildigoxin which could result in a higher serum level. |
| Acetyldigoxin | Licofelone may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level. |
| Drospirenone | The risk or severity of hyperkalemia can be increased when Licofelone is combined with Drospirenone. |
| Haloperidol | The therapeutic efficacy of Haloperidol can be increased when used in combination with Licofelone. |
| Hydralazine | Licofelone may decrease the antihypertensive activities of Hydralazine. |
| Lithium citrate | Licofelone may decrease the excretion rate of Lithium citrate which could result in a higher serum level. |
| Lithium carbonate | Licofelone may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. |
| Lithium hydroxide | Licofelone may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level. |
| Methotrexate | The serum concentration of Methotrexate can be increased when it is combined with Licofelone. |
| Pemetrexed | Licofelone may decrease the excretion rate of Pemetrexed which could result in a higher serum level. |
| Pralatrexate | Licofelone may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
| Probenecid | Probenecid may decrease the excretion rate of Licofelone which could result in a higher serum level. |
| Tenofovir disoproxil | Licofelone may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level. |
| Tenofovir alafenamide | Licofelone may decrease the excretion rate of Tenofovir alafenamide which could result in a higher serum level. |
| Tenofovir | Licofelone may decrease the excretion rate of Tenofovir which could result in a higher serum level. |
| Treprostinil | The risk or severity of bleeding can be increased when Treprostinil is combined with Licofelone. |
| Vancomycin | Licofelone may decrease the excretion rate of Vancomycin which could result in a higher serum level. |
| Mifepristone | The serum concentration of Licofelone can be increased when it is combined with Mifepristone. |
| Alendronic acid | The risk or severity of adverse effects can be increased when Licofelone is combined with Alendronic acid. |
| Lepirudin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Lepirudin. |
| Bivalirudin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Bivalirudin. |
| Alteplase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Alteplase. |
| Urokinase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Urokinase. |
| Reteplase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Reteplase. |
| Anistreplase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Anistreplase. |
| Tenecteplase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Tenecteplase. |
| Abciximab | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Abciximab. |
| Drotrecogin alfa | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Drotrecogin alfa. |
| Streptokinase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Streptokinase. |
| Dicoumarol | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Dicoumarol. |
| Argatroban | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Argatroban. |
| Ardeparin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Ardeparin. |
| Phenindione | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Phenindione. |
| Fondaparinux | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Fondaparinux. |
| Warfarin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Warfarin. |
| Pentosan polysulfate | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Pentosan polysulfate. |
| Phenprocoumon | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Phenprocoumon. |
| Dipyridamole | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Dipyridamole. |
| Heparin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Heparin. |
| Enoxaparin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Enoxaparin. |
| Epoprostenol | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Epoprostenol. |
| Acenocoumarol | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Coumarin. |
| Ximelagatran | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Ximelagatran. |
| Desmoteplase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Desmoteplase. |
| Defibrotide | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Defibrotide. |
| Ancrod | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Ancrod. |
| Beraprost | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Beraprost. |
| Prasugrel | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Prasugrel. |
| Rivaroxaban | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Rivaroxaban. |
| Sulodexide | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Sulodexide. |
| Semuloparin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Semuloparin. |
| Idraparinux | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Idraparinux. |
| Cangrelor | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Cangrelor. |
| Astaxanthin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Astaxanthin. |
| Apixaban | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Apixaban. |
| Otamixaban | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Otamixaban. |
| Amediplase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Amediplase. |
| Dabigatran etexilate | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Dabigatran etexilate. |
| Danaparoid | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Danaparoid. |
| Dalteparin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Dalteparin. |
| Tinzaparin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Tinzaparin. |
| (R)-warfarin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Ethyl biscoumacetate. |
| Nadroparin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Nadroparin. |
| Triflusal | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Triflusal. |
| Ticagrelor | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Ticagrelor. |
| Ditazole | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Ditazole. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Vorapaxar. |
| Edoxaban | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Edoxaban. |
| Sodium citrate | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Sodium citrate. |
| Dextran | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Dextran. |
| Bemiparin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Bemiparin. |
| Parnaparin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Parnaparin. |
| Desirudin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Desirudin. |
| Antithrombin Alfa | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Antithrombin Alfa. |
| Protein C | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Protein C. |
| Antithrombin III human | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Antithrombin III human. |
| Letaxaban | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Letaxaban. |
| Darexaban | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Darexaban. |
| Nafamostat | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Nafamostat. |
| Monteplase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Monteplase. |
| Gabexate | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Gabexate. |
| Fluindione | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Fluindione. |
| Protein S human | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Protein S human. |
| Brinase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Brinase. |
| Clorindione | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Tioclomarol. |
| Melagatran | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Melagatran. |
| Saruplase | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Saruplase. |
| (S)-Warfarin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with (S)-Warfarin. |
| Tocopherylquinone | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Tocopherylquinone. |
| Dabigatran | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Dabigatran. |
| Troxerutin | The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Troxerutin. |